These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 9441324

  • 1. [Use of glycopeptides in the treatment of infections caused by methicillin-resistant staphylococci].
    Bouza E, Rodríguez-Créixems M, Muñoz P.
    Rev Clin Esp; 1997 Sep; 197 Suppl 2():52-8. PubMed ID: 9441324
    [No Abstract] [Full Text] [Related]

  • 2. [Nosocomial methicillin-resistant staphylococci that remain sensitive to non-beta lactam antibiotics].
    Manfredi R, Nanetti A, Morelli S, Valentini R, Ferri M, Calza L, Chiodo F.
    Recenti Prog Med; 2003 Sep; 94(7-8):344. PubMed ID: 12868245
    [No Abstract] [Full Text] [Related]

  • 3. [Vancomycin and teicoplanin: differential aspects].
    Cobo J.
    Enferm Infecc Microbiol Clin; 1995 Dec; 13(10):600-10. PubMed ID: 8808477
    [No Abstract] [Full Text] [Related]

  • 4. Detection of an outbreak of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in a French hospital.
    Mallaval FO, Carricajo A, Delavenna F, Recule C, Fonsale N, Manquat G, Raffenot D, Rogeaux O, Aubert G, Tous J.
    Clin Microbiol Infect; 2004 May; 10(5):459-61. PubMed ID: 15113326
    [Abstract] [Full Text] [Related]

  • 5. Treatment of infective endocarditis caused by methicillin-resistant Staphylococcus aureus: teicoplanin versus vancomycin in a retrospective study.
    Huang JH, Hsu RB.
    Scand J Infect Dis; 2008 May; 40(6-7):462-7. PubMed ID: 18584532
    [Abstract] [Full Text] [Related]

  • 6. Glycopeptides in the treatment of staphylococcal infections.
    Daschner FD, Kropec A.
    Eur J Clin Microbiol Infect Dis; 1995 May; 14 Suppl 1():S12-7. PubMed ID: 7729466
    [Abstract] [Full Text] [Related]

  • 7. Activity of glycopeptides against Staphylococcus aureus infection in a rabbit endocarditis model: MICs do not predict in vivo efficacy.
    Asseray N, Jacqueline C, Le Mabecque V, Batard E, Bugnon D, Potel G, Caillon J.
    Antimicrob Agents Chemother; 2005 Feb; 49(2):857-9. PubMed ID: 15673789
    [Abstract] [Full Text] [Related]

  • 8. [Determination of the in vitro activity of 2 glycopeptides (vancomycin and teicoplanin) against methicillin-resistant Staphylococcus aureus of intrahospital origin].
    Gil M, Otth L, Wilson M, Arce E, Zaror A, Lizama V.
    Rev Med Chil; 2000 Jan; 128(1):111-2. PubMed ID: 10883531
    [No Abstract] [Full Text] [Related]

  • 9. Vascular graft infection by Staphylococcus aureus: efficacy of cefazolin, teicoplanin and vancomycin prophylaxis protocols in a rat model.
    Atahan E, Gul M, Ergun Y, Eroglu E.
    Eur J Vasc Endovasc Surg; 2007 Aug; 34(2):182-7. PubMed ID: 17481929
    [Abstract] [Full Text] [Related]

  • 10. [Pharmacological considerations in the economic evaluation of glycopeptides].
    García-Quetglas E, Sádaba B, Honorato J.
    Rev Clin Esp; 1997 Sep; 197 Suppl 2():68-73. PubMed ID: 9441326
    [No Abstract] [Full Text] [Related]

  • 11. Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals.
    Cartolano GL, Cheron M, Benabid D, Leneveu M, Boisivon A, Association of Hospital Bacteriologists, Virologists and Hygiene Professionals.
    Clin Microbiol Infect; 2004 May; 10(5):448-51. PubMed ID: 15113324
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
    Madrigal AG, Basuino L, Chambers HF.
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918
    [Abstract] [Full Text] [Related]

  • 13. Vancomycin versus teicoplanin in the therapy of experimental methicillin-resistant Staphylococcus aureus (MRSA) meningitis.
    Sipahi OR, Arda B, Yurtseven T, Sipahi H, Ozgiray E, Suntur BM, Ulusoy S.
    Int J Antimicrob Agents; 2005 Nov; 26(5):412-5. PubMed ID: 16221540
    [Abstract] [Full Text] [Related]

  • 14. Tolerance to the glycopeptides vancomycin and teicoplanin in coagulase-negative staphylococci.
    Bourgeois I, Pestel-Caron M, Lemeland JF, Pons JL, Caron F.
    Antimicrob Agents Chemother; 2007 Feb; 51(2):740-3. PubMed ID: 17116684
    [Abstract] [Full Text] [Related]

  • 15. [Are we being threatened by multiresistant strains of Staphylococcus aureus?].
    Aepfelbacher M.
    MMW Fortschr Med; 2005 Jan 27; 147(4):33-5, 37. PubMed ID: 15745339
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness of teicoplanin versus vancomycin lock therapy in the treatment of port-related coagulase-negative staphylococci bacteraemia: a prospective case-series analysis.
    Del Pozo JL, García Cenoz M, Hernáez S, Martínez A, Serrera A, Aguinaga A, Alonso M, Leiva J.
    Int J Antimicrob Agents; 2009 Nov 27; 34(5):482-5. PubMed ID: 19713086
    [Abstract] [Full Text] [Related]

  • 17. Bacterial endocarditis treated with intramuscular teicoplanin.
    Chauhan S, D'Cruz S, Sachdev A, Singh R.
    Singapore Med J; 2007 Sep 27; 48(9):e248-9. PubMed ID: 17728952
    [Abstract] [Full Text] [Related]

  • 18. Emergence of vancomycin-intermediate Staphylococcus aureus and S. sciuri, Greece.
    Tsakris A, Papadimitriou E, Douboyas J, Stylianopoulou F, Manolis E.
    Emerg Infect Dis; 2002 May 27; 8(5):536-7. PubMed ID: 11996696
    [No Abstract] [Full Text] [Related]

  • 19. In vitro activity of vancomycin and teicoplanin against staphylococci in intensive care units.
    Kucukates E.
    Natl Med J India; 2004 May 27; 17(2):117. PubMed ID: 15141614
    [No Abstract] [Full Text] [Related]

  • 20. Therapy for methicillin-resistant Staphylococcus aureus.
    Torres-Tortosa M, Caballero-Granado FJ, Canueto J.
    N Engl J Med; 2006 Nov 16; 355(20):2153-4; author reply 2155. PubMed ID: 17120350
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.